You Position: Home > Paper
Meta-analysis of safety and efficacy of antiangiogenic drug aflibercept for metastatic colorectal cancer
( views:59, downloads:0 )
- Author:
- No author available
- Journal Title:
- World Chinese Journal of Digestology
- Issue:
- 1
- DOI:
- 10.11569/wcjd.v28.i1.18
- Key Word:
- 结肠癌;阿柏西普;FOLFOX4/FOLFIRI;Meta分析
Abstract： 背景 目前国内外较多研究发现阿柏西普联合FOLFOX4/FOLFIRI方案治疗转移性结肠癌(metastatic colorectal cancer,mCRC)具有比较好的疗效,本研究在国内外多项研究的基础上,对于其疗效和安全性进行Meta分析,进而提供循证医学相关的依据.目的 运用Meta分析系统性研究和评价阿柏西普在治疗mCRC中的治疗效果和安全性.方法 检索从2009-01/2019-01阿柏西普联合FOLFOX4/FOLFIRI方案治疗mCRC的对照试验,包括:中国知网数据库、维普数据库、万方数据库、中国生物医学文献数据库、PubMed、The Cochrane Library和EMBASE,以Cochrane系统评价手册为文献评价标准对于文献进行评价,对于所筛选的文献用Revman 5.3软件进行Meta分析,95％可信区间估计.结果 本研究共纳入5篇文献,Meta分析结果表明:实验组患者在3年总生存率和3年无进展生存率方面的生存率高于对照组,差异有统计学意义(OR=0.52,95％CI:0.35-0.79,P=0.002;OR=0.63,95％CI:0.45-0.89,P=0.008).实验组患者在总不良反应方面的发生率低于对照组患者,二者差异有统计学意义(OR=0.58,95％CI:0.40-0.84,P=0.004),在腹泻、白细胞减少、食欲减退、恶心呕吐发生率均低于对照组,二者差异有统计学意义(P＜0.05).结论 阿柏西普联合FOLFOX4/FOLFIRI方案治疗mCRC较FOLFOX4/FOLFIRI治疗mCRC的效果好且安全性较高.
- [1]朱磊林,陈健,王刚,等.探讨贝伐单抗治疗转移性结直肠癌患者血清VEGF水平与疗效的关系[J].2014,(8).
- [2]周斌芳,钟雪梅,杨克虎,等.间歇导尿与留置导尿治疗尿潴留的系统评价[J].2012,(23).
- [3]Alessandro,Pastorino,Maria,Di Bartolomeo,Evaristo,Maiello,etc.Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.[J].2018,17(3).
- [4]VanCutsem,E.,Khayat,D.,Vandecaveye,V.,etc.Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: Results from the expansion cohort of a phase i study[J].2013,49(4).
- [5]Paul Ruff,Eric Van Cutsem,Radek Lakomy,etc.Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial[J].2018,9(1).
- [6]Leung, Li,Brigette By, Ma.Colorectal cancer in Chinese patients: current and emerging treatment options.[J].2014,7.
- [7]Ohtsu,A.,Boku,N.,Yamazaki,K.,etc.A phase i study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer[J].2013,31(4).
- [8]Benoist,Chibaudel,Jean-Baptiste,Bachet,Thierry,André,etc.Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first-line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.[J].2019,54(4).
- [9]Eveno,C.,Pocard,M..VEGF levels and the angiogenic potential of the microenvironment can affect surgical strategy for colorectal liver metastasis[J].2012,6(6).
- [10]Bjarnason,G.,Tang,P.A.,Virik,K.,etc.Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer[J].2012,18(21).
- [11]Sagaert, Xavier,Margherini, Emmanuelle,Lambrechts, Diether,etc.Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting[J].2015,113(7).
- [12]Jin,Li,Ruihua,Xu,Shukui,Qin,etc.Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study.[J].2017,14(20).
- [13]Van Cutsem, Eric,Joulain, Florence,Hoff, Paulo M.,etc.Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing A[J].2016,11(3).
- [14].FDA Approves Regorafenib (Stivarga) for GIST[J].2013,27(3).
- [15]Martinelli,E.,Troiani,T.,Morgillo,F.,etc.Emerging VEGF-receptor inhibitors for colorectal cancer[J].2013,18(1).
- [16]Yusof Mastura Md,Abdullah Nik MA,Sharial MSN Mohd,etc.Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer[J].2016,17(3).
- [17]Josep, Tabernero,Eric, Van Cutsem,Radek, Lakomy,etc.Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.[J].2014,50(2).